$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
瑞格非尼治疗结直肠癌疗效优于安慰剂
2025-10-19 11:44:20
Check Details
瑞格非尼对索拉非尼治疗后进展晚期肝细胞癌患者的获益-风险总结
2025-10-19 11:44:20
Check Details
瑞戈非尼治疗转移性结直肠癌(mCRC)患者
2025-10-19 11:44:20
Check Details
瑞格非尼治疗结直肠癌患者
2025-10-19 11:44:20
Check Details
瑞格非尼治疗长期有效的结直肠癌患者的临床结果和分子特征
2025-10-19 11:44:20
Check Details
瑞格非尼用于转移性结直肠癌患者的治疗
2025-10-19 11:44:20
Check Details
瑞格非尼 vs Lonsurf 在化疗难治性转移性结直肠癌患者中的倾向评分分析:日本多中心观察研究
2025-10-19 11:44:20
Check Details
瑞格非尼治疗转移性结直肠癌(mCRC)疗效
2025-10-19 11:44:20
Check Details
瑞格非尼治疗难治性转移性结直肠癌
2025-10-19 11:44:20
Check Details
瑞格非尼治疗中国转移性结直肠癌患者疗效
2025-10-19 11:44:20
Check Details
瑞格非尼在胃肠道间质瘤患者中的治疗模式和疗效
2025-10-19 11:44:20
Check Details
瑞格非尼对肝细胞癌患者疗效的暴露-反应关系
2025-10-19 11:44:20
Check Details
1
2
...
1598
1599
1600
1601
1602
1603
1604
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
4
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
5
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
6
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
7
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
8
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
9
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
10
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
11
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
12
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use